SynerK’s SNK-2726 Gets FDA Green Light for Phase I Hypertension Study
SynerK, an RNA-targeted therapy developer with operations in Boston, US, and Beijing and Suzhou, China,...
SynerK
Huadong Medicine Partners with SynerK PharmaTech for Hypertension siRNA Drug Development
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK...
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou,...
Sciwind Biosciences Partners with SynerK for siRNA Therapeutics Development
Hangzhou Sciwind Biosciences Co., Ltd has announced a research partnership with SynerK Inc. The collaboration...